DNA
Ginkgo Bioworks Holdings, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+43/100
Last price
12.37
▼ 2.61 (17.42%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
12.35
Prev close
14.98
Day high
18.22
Day low
12.11
Volume
13.13M
Market cap
$835.69M
P/E (TTM)
—
52W range
5.37 – 18.22
Day trading desk
Gap from prior close
-17.56%
Prior close 14.98
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
1.21%
12.35 – 12.50
Position in range
13%
Near session low
ATR (14D)
1.70
13.73% of price
Prior day high
15.48
PDH
Prior day low
12.48
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 1.50M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+3.76%
+1.8%
1M
+78.56%
+77.4%
3M
+36.82%
+32.3%
6M
+81.96%
+63.8%
YTD
+49.34%
+35.1%
1Y
-23.11%
-39.5%
3Y
-82.86%
-165.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on DNA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+569.40K
Net buying
Buy transactions
10
1.12M shares
Sell transactions
11
548.66K shares
Net transactions
+21
Buys less sells
Sell : buy shares
0.5 : 1
Mixed
Insider-held shares
2.99M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | HENRY CHRISTIAN O Director |
SELL | 5.00K | $35.41K | Direct |
| Aug 24, 26 | COEN STEVEN P. Chief Financial Officer |
SELL | 330 | $2.30K | Direct |
| Aug 21, 26 | COEN STEVEN P. Chief Financial Officer |
— | 743 | — | Direct |
| Jul 17, 26 | COEN STEVEN P. Chief Financial Officer |
SELL | 752 | $5.94K | Direct |
| Jul 16, 26 | COEN STEVEN P. Chief Financial Officer |
— | 1.49K | — | Direct |
| May 22, 26 | COEN STEVEN P. Chief Financial Officer |
SELL | 307 | $2.56K | Direct |
| May 21, 26 | COEN STEVEN P. Chief Financial Officer |
— | 743 | — | Direct |
| Apr 17, 26 | COEN STEVEN P. Chief Financial Officer |
SELL | 324 | $2.58K | Direct |
| Apr 16, 26 | COEN STEVEN P. Chief Financial Officer |
— | 743 | — | Direct |
| Apr 13, 26 | COEN STEVEN P. Chief Financial Officer |
SELL | 33.17K | $212.76K | Direct |
| Apr 10, 26 | CANTON BARTHOLOMEW Beneficial Owner of more than 10% of a Class of Security |
SELL | 124.73K | $802.49K | Indirect |
| Apr 10, 26 | SHETTY RESHMA PADMINI President |
SELL | 124.73K | $802.49K | Direct |
| Apr 10, 26 | COEN STEVEN P. Chief Financial Officer |
— | 73.92K | — | Direct |
| Apr 9, 26 | CANTON BARTHOLOMEW Beneficial Owner of more than 10% of a Class of Security |
SELL | 26.27K | $175.07K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CANTON BARTHOLOMEW |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
COEN STEVEN P. |
Chief Financial Officer | 51.85K | Sale |
DMYTRUK MARK E |
Chief Financial Officer | 46.23K | Sale |
HANNAN KATHY HOPINKAH |
Director | 15.00K | Conversion of Exercise of derivative security |
HENRY CHRISTIAN O |
Director | 19.31K | Sale |
KELLY JASON R |
Chief Executive Officer | 316.48K | Sale |
KOSURI SRI |
Director | 24.07K | Conversion of Exercise of derivative security |
SANKAR SHYAM |
Director | 72.37K | Conversion of Exercise of derivative security |
SHETTY RESHMA PADMINI |
President | 436.42K | Sale |
SLOAN HARRY EVANS |
Director | 271.42K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$835.69M
Enterprise value$937.64M
Revenue (TTM)$132.42M
Gross profit$90.10M
EBITDA$-261.62M
Net income$-309.64M
EPS (TTM)$-5.06
Free cash flow$-72.40M
Total cash$302.16M
Total debt$404.11M
Book value / share$6.60
Shares outstanding55.38M
Float49.88M
Short % of float13.36%
Dividend yield0.00%
Beta (5Y)1.80
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.28
PEG ratio—
Price / sales—
Price / book1.88
EV / revenue7.08
EV / EBITDA-3.58
Gross margin68.04%
Operating margin-284.99%
Profit margin-219.61%
Return on equity-59.94%
Return on assets-16.72%
Debt / equity96.15
Current ratio4.57
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $170.16M | $227.04M | $251.46M | $477.71M | -25.1% |
| Operating revenue | $170.16M | $227.04M | $251.46M | $477.71M | -25.1% |
| Cost of revenue | $46.97M | $44.55M | $54.01M | $204.22M | +5.4% |
| Gross profit | $123.18M | $182.50M | $197.45M | $273.49M | -32.5% |
| Research & development | $243.77M | $424.06M | $580.62M | $1.05B | -42.5% |
| Selling, general & admin | $183.29M | $246.16M | $385.02M | $1.43B | -25.5% |
| Total operating expense | $427.06M | $670.22M | $965.65M | $2.48B | -36.3% |
| Operating income | -$303.88M | -$487.73M | -$768.20M | -$2.21B | +37.7% |
| Net interest income | $22.62M | $38.52M | $57.12M | $20.16M | -41.3% |
| Pre-tax income | -$313.60M | -$547.51M | -$892.94M | -$2.12B | +42.7% |
| Tax provision | -$837.00K | -$479.00K | -$71.00K | -$15.03M | -74.7% |
| Net income | -$312.76M | -$547.03M | -$892.87M | -$2.10B | +42.8% |
| Net income to common | -$312.76M | -$547.03M | -$892.87M | -$2.10B | +42.8% |
| Basic EPS | -5.64 | -10.54 | -18.37 | -50.00 | +46.5% |
| Diluted EPS | -5.64 | -10.54 | -18.37 | -50.00 | +46.5% |
| EBIT | -$313.60M | -$547.41M | -$892.85M | -$2.12B | +42.7% |
| EBITDA | -$254.61M | -$484.39M | -$822.34M | -$2.08B | +47.4% |
| Basic shares | 55.46M | 51.89M | 48.61M | 41.98M | +6.9% |
| Diluted shares | 55.46M | 51.89M | 48.61M | 42.00M | +6.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $167.20M | $561.57M | $944.07M | $1.32B | — | -70.2% |
| Cash & short-term investments | $422.62M | $561.57M | $944.07M | $1.32B | — | -24.7% |
| Accounts receivable | $24.03M | $21.86M | $17.16M | $82.47M | — | +9.9% |
| Inventory | — | — | $46.00K | $4.36M | $3.36M | — |
| Total current assets | $471.84M | $602.74M | $1.00B | $1.45B | — | -21.7% |
| Property, plant & equipment | $528.70M | $598.15M | $394.99M | $718.79M | — | -11.6% |
| Goodwill & intangibles | $56.92M | $72.51M | $131.98M | $171.25M | — | -21.5% |
| Total assets | $1.12B | $1.38B | $1.67B | $2.54B | — | -18.7% |
| Total current liabilities | $95.97M | $107.27M | $163.86M | $172.96M | — | -10.5% |
| Total debt | $439.88M | $467.73M | $239.31M | $442.59M | — | -6.0% |
| Total liabilities | $611.11M | $661.39M | $568.19M | $803.04M | — | -7.6% |
| Retained earnings | -$6.15B | -$5.84B | -$5.29B | -$4.40B | — | -5.4% |
| Shareholder equity | $508.59M | $716.06M | $1.10B | $1.74B | — | -29.0% |
| Working capital | $375.87M | $495.48M | $837.89M | $1.28B | — | -24.1% |
| Net tangible assets | $451.67M | $643.55M | $965.17M | $1.57B | — | -29.8% |
| Shares issued | 58.21M | 54.37M | 50.03M | 47.30M | — | +7.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$312.76M | -$547.03M | -$892.87M | -$2.11B | — | +42.8% |
| Depreciation & amortisation | $58.99M | $63.02M | $70.51M | $42.55M | — | -6.4% |
| Stock-based compensation | $81.55M | $112.34M | $229.88M | $1.93B | — | -27.4% |
| Change in working capital | -$44.09M | -$89.67M | $29.84M | -$37.01M | — | +50.8% |
| Operating cash flow | -$171.06M | -$319.58M | -$295.50M | -$252.20M | — | +46.5% |
| Capital expenditure | -$7.67M | -$62.54M | -$40.80M | -$52.27M | — | +87.7% |
| Investing cash flow | -$240.29M | -$62.24M | -$80.69M | -$67.39M | — | -286.1% |
| Share buybacks | — | — | $0 | $0 | -$25.00M | — |
| Financing cash flow | $17.77M | -$1.74M | -$3.22M | $95.34M | — | +1,122.1% |
| Free cash flow | -$178.72M | -$382.13M | -$336.30M | -$304.47M | — | +53.2% |
| End cash position | $212.37M | $605.74M | $989.58M | $1.37B | — | -64.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $20.16M | $19.47M | $33.40M | $38.84M | $39.13M | — | +3.5% |
| Operating revenue | $20.16M | $19.47M | $33.40M | $38.84M | $39.13M | — | +3.5% |
| Cost of revenue | $1.72M | $3.10M | $7.30M | $12.80M | $5.38M | — | -44.5% |
| Gross profit | $18.44M | $16.38M | $26.09M | $26.04M | $33.75M | — | +12.6% |
| Research & development | $46.21M | $49.92M | $50.13M | $69.35M | $53.37M | — | -7.4% |
| Selling, general & admin | $30.77M | $37.83M | $46.01M | $44.95M | $34.98M | — | -18.6% |
| Total operating expense | $76.98M | $87.75M | $96.14M | $114.31M | $88.35M | — | -12.3% |
| Operating income | -$58.55M | -$71.37M | -$70.05M | -$88.27M | -$54.60M | — | +18.0% |
| Net interest income | $3.23M | $3.60M | $4.71M | $5.74M | $6.08M | — | -10.1% |
| Pre-tax income | -$57.19M | -$76.14M | -$81.39M | -$80.75M | -$53.48M | — | +24.9% |
| Tax provision | $128.00K | -$80.00K | -$643.00K | $1.00K | -$283.00K | — | +260.0% |
| Net income | -$46.71M | -$82.59M | -$80.75M | -$80.75M | -$60.30M | — | +43.4% |
| Net income to common | -$46.71M | -$82.59M | -$80.75M | -$80.75M | -$60.30M | — | +43.4% |
| Basic EPS | -0.75 | -1.39 | — | -1.45 | -1.10 | -1.68 | +46.0% |
| Diluted EPS | -0.75 | -1.39 | — | -1.45 | -1.10 | -1.68 | +46.0% |
| EBIT | -$58.55M | -$71.37M | -$79.77M | -$88.27M | -$54.60M | — | +18.0% |
| EBITDA | -$46.23M | -$58.58M | -$66.10M | -$73.02M | -$39.35M | — | +21.1% |
| Basic shares | 62.09M | 59.56M | — | 55.63M | 54.86M | 54.24M | +4.2% |
| Diluted shares | 62.09M | 59.56M | — | 55.63M | 54.86M | 54.24M | +4.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $84.53M | $143.86M | $167.20M | $111.06M | $203.57M | -41.2% |
| Cash & short-term investments | $302.16M | $373.46M | $422.62M | $461.86M | $473.69M | -19.1% |
| Accounts receivable | $13.01M | $19.82M | $24.03M | $21.43M | $22.15M | -34.3% |
| Total current assets | $332.54M | $409.95M | $471.84M | $506.08M | $523.02M | -18.9% |
| Property, plant & equipment | $504.85M | $516.82M | $528.70M | $544.79M | $562.15M | -2.3% |
| Goodwill & intangibles | $44.39M | $48.86M | $56.92M | $61.52M | $66.15M | -9.2% |
| Total assets | $990.05M | $1.03B | $1.12B | $1.19B | $1.23B | -4.2% |
| Total current liabilities | $72.74M | $79.59M | $95.97M | $115.28M | $96.72M | -8.6% |
| Total debt | $404.11M | $410.70M | $439.88M | $422.87M | $428.83M | -1.6% |
| Total liabilities | $569.76M | $589.92M | $611.11M | $629.38M | $618.06M | -3.4% |
| Retained earnings | -$6.28B | -$6.23B | -$6.15B | -$6.07B | -$5.99B | -0.7% |
| Shareholder equity | $420.28M | $443.15M | $508.59M | $559.78M | $612.95M | -5.2% |
| Working capital | $259.80M | $330.36M | $375.87M | $390.80M | $426.31M | -21.4% |
| Net tangible assets | $375.90M | $394.29M | $451.67M | $498.26M | $546.80M | -4.7% |
| Shares issued | 63.71M | 61.66M | 58.21M | 56.84M | 55.43M | +3.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$57.32M | -$76.06M | -$80.75M | -$95.51M | -$53.19M | — | +24.6% |
| Depreciation & amortisation | $12.31M | $12.80M | $13.66M | $15.26M | $15.25M | — | -3.8% |
| Stock-based compensation | $7.59M | $15.85M | $21.03M | $24.33M | $18.80M | — | -52.1% |
| Change in working capital | -$13.15M | -$14.18M | -$23.59M | $10.48M | -$24.13M | — | +7.3% |
| Operating cash flow | -$44.27M | -$46.69M | -$47.68M | -$31.61M | -$40.25M | — | +5.2% |
| Capital expenditure | -$2.62M | -$1.93M | -$5.00K | — | -$38.00K | -$7.62M | -35.5% |
| Investing cash flow | $11.09M | $23.13M | $95.10M | -$72.82M | -$63.89M | — | -52.1% |
| Financing cash flow | $16.49M | -$19.00K | $8.14M | $9.94M | -$98.00K | — | +86,884.2% |
| Free cash flow | -$46.89M | -$48.62M | -$47.68M | -$31.61M | -$40.29M | — | +3.6% |
| End cash position | $172.01M | $188.67M | $212.37M | $156.96M | $251.35M | — | -8.8% |
Options analytics
Put / call volume
0.88
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.00
-83.9% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
2.10K
Contracts, this expiry
Put volume
1.84K
Contracts, this expiry
Heaviest call OI
2.00
0 contracts
Heaviest put OI
5.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.70 | -0.73 | -4.7% |
| Mar 2026 | -1.34 | -1.39 | -3.7% |
| Dec 2025 | -1.11 | -0.77 | +30.5% |
| Sep 2025 | -1.24 | -1.45 | -16.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.58 | 1 | $21.58M | -44.4% |
| Next quarter | -0.82 | 1 | $23.85M | -28.6% |
| Current year | -3.20 | 1 | $85.03M | -50.0% |
| Next year | -2.90 | 1 | $96.40M | +13.4% |
Analyst targets & ownership
Mean target$7.00
High target$9.00
Low target$5.00
Implied upside-43.41%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 0
Hold1
Sell / Strong sell1 / 1
Held by insiders4.43%
Held by institutions73.73%
Institutions holding252
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.70
+5.74% from price
SMA 20
9.57
+29.66% from price
SMA 50
8.33
+49.02% from price
SMA 100
8.51
+45.39% from price
SMA 200
8.38
+48.14% from price
EMA 12
11.44
+8.10% from price
EMA 26
9.91
+24.81% from price
EMA 50
9.04
+36.82% from price
RSI (14)
62.7
Neutral
MACD (12,26,9)
1.53
Hist 0.47
ATR (14)
1.70
13.69% of price
Realised vol 30D
123.1%
Annualised
Bollinger upper
14.57
20, 2σ
Bollinger lower
4.58
20, 2σ
50 / 200 cross
Death
8.33 vs 8.38
Trend bias
Above 200
+48.14%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.93
More volatile than market
Correlation to SPY
0.38
Loosely linked
Realised vol 30D
123.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-65.9%
Peak to trough
Max drawdown 5Y
-99.1%
Peak to trough
ATR 14
1.70
13.69% of price
Beta (reported)
1.80
5Y monthly, from filing
Short interest
Shares short
7.17M
Prior 5.60M
Change vs prior
+28.0%
Shorts adding
% of float
13.36%
Elevated
% of shares out
10.64%
Against total outstanding
Days to cover
6.4
Crowded exit
Float
49.88M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 4, 26 | BTIG | MAINTAINED | Sell | Sell |
| Aug 7, 26 | TD Cowen | DOWNGRADE | Buy | Hold |
| Mar 12, 26 | BTIG | MAINTAINED | Sell | Sell |
| Jan 8, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 25, 25 | BTIG | MAINTAINED | Sell | Sell |
| Sep 20, 24 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 23, 24 | BTIG | MAINTAINED | Sell | Sell |
| Jul 9, 24 | Goldman Sachs | MAINTAINED | Sell | Sell |
| Jun 26, 24 | BTIG | MAINTAINED | Sell | Sell |
| May 15, 24 | BTIG | DOWNGRADE | Neutral | Sell |
| May 15, 24 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| May 10, 24 | William Blair | DOWNGRADE | Market Perform | Underperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:40
Split dateAug 20, 2024
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEFA14A · 2026-04-29
Corporate Changes & Voting Matters
8-K · 2026-04-07
Corporate Changes & Voting Matters
8-K · 2026-02-27
Headlines
This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled
Motley Fool · 2d ago
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Zacks · 6d ago
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
Business Wire · 8d ago
What Needs To Be True To Buy Twist Bioscience Stock Now?
Trefis · 11d ago
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks · 13d ago
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
Zacks · 19d ago
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts
Zacks · 20d ago
Ginkgo Datapoints to Supply Discovery Data for Eli Lilly's TuneLab Network
MT Newswires · 21d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.